Mallinckrodt reports positive efficacy results from Phase III study of pain drug
Mallinckrodt has released positive efficacy results from the Phase III clinical trial of MNK-155, an investigational extended-release oral formulation of hydrocodone and acetaminophen evaluated for the management of moderate to moderately severe acut…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Acetaminophen | Clinical Trials | Hydrocodone | Lortab | Pain | Pain Management | Pharmaceuticals | Study | Vicodin